Sequenom this week hired Betty Dragon as senior vice president of research and development.
Dragon has worked since 1990 at Roche Molecular Systems, most recently as senior vice president of global standardization and vice president of diagnostics development. There, Dragon led the development and commercialization of Roche's Amplicor, Cobas Amplicor, Cobas AmpliPrep and Cobas TaqMan reagent product lines.
She earned her PhD in virology and cell biology from Albert Einstein College of Medicine at Yeshiva University in New York.
ChondroGene has hired David Tyler as director of product development and quality assurance.
Tyler most recently worked at Prodesse and Third Wave Technologies, where he managed product development and GMP manufacturing operations and helped both firms obtain ISO 13485 certification.
Tyler has also held research and management positions at the Howard Hughes Medical Institute at the University of California, Berkeley; the University of California, San Francisco; and Lawrence Berkeley National Laboratory.
He has a BA in biochemistry and an MS in microbiology from UC Berkley.
Amir Avniel has been named president and CEO of Rosetta Genomics, while Nathan Hod has joined the company's board of directors and Yoav Chelouche has been elected to serve as the new chairman of the board.
Avniel joined the company in 2000 and was formerly president, CTO, and COO.
Chelouche has been a member of the Rosetta Genomics board of directors since 2001, and is currently a managing partner at Aviv Venture Capital. He previously served as president and CEO of Scitex.
Hod co-founded DSPC, a manufacturer of chip sets for the wireless industry that was acquired by Intel in 1999.
Genzyme this week launched its FLT3 Mutation Analysis test and a WT1 RQ-PCR test. The FLT3 test is intended to help provide physicians with a prognosis for patients on chemotherapy, by detecting a common genetic abnormality associated with poor survival in patients with AML. The WT1 PQ-PCR test is intended to help physicians to detect signs of early relapse in AML patients during and after therapy by detecting minimal residual disease.
Cepheid this week launched in Europe its Smart EBV Assay for detecting Epstein-Barr virus and determining viral load. The test runs on Cepheid's SmartCycler platform, and it carries the European Community's CE Mark for IVD products. Smart EBV is intended for rapid detection and quantitation of EBV viral load. The assay features a standardized method that can be used with blood cells, serum, or plasma in 30 to 40 minutes, the company said.
Gene Logic launched its SNP Microarray Genotyping Service this week. As part of its service, Gene Logic will process whole blood, tissue, or DNA samples and generate up to 500,000 genotypes per sample using commercially available arrays.
CombiMatrix last week launched an updated version of its Influenza A Typing Microarray. The upgraded array now includes sequences that had not been previously available, the company said.